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Editorial
After the use of antiviral drugs in the treatment of hepatitis
B virus (HBV) infection, we found new therapeutic
options for non-responders to interferon (IFN). Addition-
ally, those could not be treated previously by IFN, such as
cirrhotics have been given effective antivirals. However,
the parameters to determine the efficacy, the outcome
measures, and the duration of the treatment emerged as
unresolved issues by the treatment with antivirals. Resist-
ance to antivirals is also a challenge and its definition,
detection, and management are new controversial topics
in the area of HBV treatment.
Now, the clinician has a wider choice of antivirals: in
addition to IFNs, lamivudine, adefovir, entecavir, telbivu-
dine, and tenofovir have been approved for treating
chronic HBV infection [1,2]. As the HBV treatment studies
are published, we see several comparisons of the antivirals
[3-5]. Updated EASL guideline gave the comparisons of
the HBV drugs [6]. However comparing efficacies or other
aspects of two or more antivirals in a simple way may give
misleading results.
Recently, Feld and Ghany [7] summarized the complexity
of the issue of hepatitis B treatment and simply compared
the response to approved antiviral agents among hepatitis
B e antigen-positive patients. The reviewed studies are the
main ones showing the efficacy of the given drug and
mostly represent the ones submitted to FDA. They gener-
ally include sufficient number of patients to conclude
about the efficacy of the drugs. Lamivudine was the com-
parator in some of the studies and the results obtained
from the use of lamivudine were reported as well. There
are several differences between these studies by many
aspects (Table 1) [8-12]. Different methods were used in
these studies for detection and quantification HBV DNA.
Also sensitivity, detection limit and dynamic range of
quantification of these tests make them difficult to com-
pare [13]. Only baseline HBV level which is lower more
than 1 log (corresponds to several folds) in adefovir study,
for example, makes it almost impossible to compare.
Combined data of three studies were given for lamivu-
dine, however virological response criterion differed
among these studies.
ALT is another issue: Baseline mean ALT levels may not be
comparable. Additionally, ALT level as an inclusion crite-
rion varied: greater than 1 time the upper limit of the nor-
mal range for pegylated interferon [8], 1.3 times for
entecavir [9] and telbivudine [10], and 1.2 times for ade-
fovir [11].
Patient numbers, genotype distributions, treatment dura-
tions, previous treatment, and probably many other dif-
ferences exist among the studies compared, discouraging
to make a head-to-head comparison. Asian race for exam-
ple, is associated with poor response to interferon treat-
ment [14], and the rate of this race is highest in pegylated
IFN study.
Considering the role of high ALT and low DNA on treat-
ment response, a comparison of efficacy of any two drugs
should include the details of distribution of these param-
eters in the study population. Only the telbivudine study
described the stratification of the patients according to
DNA levels.
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Table 1: Differing characteristics of the studies comparing the response rates in HBeAg-positive patients
Pegylated-IFN-α2a, 
180 μg once Weekly
[8]
Lamivudine 
100 mg/d
[8-10]
Adefovir
10 mg/d
[11]
Entecavir 
0.5 mg/d
[9]
Telbivudine 
600 mg/d
[10]
Tenofovir 
300 mg/d
[12]
Mean age (years) 32.5 31.6 to 35 34 35 32 34
Male gender (%) 79 74 to 79 76 77 74 68
Asian race (%) 87 57 to 87 60 58 82 36
Patient number 271 272 to 463 171 354 399 176
Previous treatment Conventional IFN 11%, 
lamivudine 11%
Conventional IFN 11%/IFN 13% 
and lamivudine 3%/NA
IFN 
(24% among all arms)
IFN 13% and lamivudine 3% NA IFN 17%, lamivudine or 
emtricitabine 5%
Baseline HBV-DNA (log10 cp/ml) 9.9 9.5 to 10.1 8.25 9.62 9.51 8.64
Baseline ALT 114.6 102 to 159 139 140.5 146 142
Baseline necro-inflammatory score NA 7.3 to 7.7 7.37 7.8 7 8.3
Baseline fibrosis score NA 2.2 to 2.3 1.64 2.3 2.2 2.3
Genotypes 
(%, A/B/C/D/others)
8/28/60/3/1 7/30/58/4/1 (ref 8) 28/22/25/15/
11 (ref 9)
NA 27/19/31/10/13 NA 24/14/25/32/5
Treatment duration (weeks) 48 48 to 52 48 48 52 48
Virological response criterion (HBV 
DNA level)
<400 cp/ml <400 cp/ml (ref 8), <0.7 MEq/ml 
(ref 10), <300 cp/ml (ref 10)
<300 cp/ml <0.7 MEq/ml <300 cp/ml <400 cp/ml
IFN: interferon, NA: not available, MEq/ml: mili-equivalent/mililiter, cp/ml: copies/milliliter.Annals of Clinical Microbiology and Antimicrobials 2009, 8:6 http://www.ann-clinmicrob.com/content/8/1/6
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Resistance is another important issue in the treatment of
HBV with antivirals. The published clinical trials have
used varying definitions of efficacy, failure, and resistance
based on different measures of virologic responses [15]. If
we analyze the resistance outcomes in the studies, we see
that although some studies included all patients to the
tests for antiviral resistance [16,17] some others included
only those with a viral rebound [18,19]. The methods
used to detect the resistance also differ: Although the
majority of the studies used direct sequencing [20], restric-
tion fragment length polymorphism [21] and line-probe,
matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry [22] were used in some others. Study
design differs in the studies and reported resistance rates
should be evaluated regarding the design. In entecavir
study, patients who had a response (defined by an HBV
DNA level below 0.7 megaequivalents [MEq] per milliliter
and HBeAg loss) or a nonresponse (defined by an HBV
DNA level of 0.7 MEq per milliliter or greater) discontin-
ued study treatment at week 52 [9]. Patients who had only
a virologic response (defined by an HBV DNA level below
0.7 MEq per milliliter and no HBeAg loss) were offered
continued study therapy for up to 96 weeks. This design,
especially discontinuation of the therapy in nonrespond-
ers may decrease the risk of resistance. This unique feature
of the study may underestimate the resistance.
Studies in HBeAg-negative patients may have similar
problems, especially in inclusion criteria and response
definitions [23]. A review defined virological response as
"decrease of serum HBV DNA to PCR-undetectable levels
(preferably) or <2000 IU/mL (4 log10 copies/mL) [5]. The
entecavir study used "HBV DNA <300 copies/ml by PCR
assay" [24] and the adefovir study used "<400 copies/ml"
[25]. Clevudine study, finally, used hybride capture with
lower limit of detection of <4700 copies/mL and then if it
remains undetectable, used PCR with lower limit of detec-
tion of 300 copies/mL [26].
A simple comparison of several drugs in differing study
characteristics may not give reliable conclusive informa-
tion to the reader. Unless randomizing the patients in the
same study design, it seems difficult to compare the effica-
cies of any given drugs. When giving such comparisons,
the reader should be warned against the difference among
study characteristics and better, the main differences
should also be included.
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